We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
The concept of autoregulation of total blood flow and its role in hypertension.
American Journal of Medicine 1980 June
Arterial vascular resistance to blood flow is increased in every known form of established hypertension. The proposed mechanisms responsible for these alterations in vascular resistance include humoral factors, the nervous system and local autoregulatory events. This study focuses on the potential importance of the phenomenon of tissue autoregulation as a factor in vascular resistance. Nearly all individual organ systems can locally adjust their vascular resistance (autoregulate) to maintain appropriate blood flow, so that the sum of all the tissue resistances determines the total blood flow through the circulation (cardiac output). The extent to which these local autoregulatory mechanisms can influence hemodynamic events associated with various types of hypertension is evaulated. It is concluded that even slight fluid retention over periods of weeks and months enables autoregulatory mechanisms to sustain a 50 per cent increase in arterial pressure with only a 5 per cent observed increase in cardiac output. In some forms of hypertension, these mechanisms appear to explain the observed hemodynamic changes (i.e., low renin essential hypertension or primary aldosteronism). In other forms, there may be no reason for autoregulation to occur, so the mechanism might be of no consequence in determining the vascular resistance. The evidence indicates that regulation of cardiac output cannot explain the cause of hypertension, but local autoregulation of flow must be carefully considered if we are to understand fully the hemodynamic events associated with various forms of hypertension.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app